Participants may join the discussion by dialing 800-347-6865 for domestic callers or 203-518-9757 for international access, using the conference ID NBIX. The company will host the live webcast through the investor relations section of its corporate website at www.neurocrine.com. An archived version of the presentation will remain accessible online for approximately one month, starting one hour after the event concludes.

Neurocrine Biosciences continues to manage a portfolio focused on neurological, psychiatric, endocrine, and immunological disorders. The company’s current offerings include treatments for tardive dyskinesia, Huntington’s disease-associated chorea, and congenital adrenal hyperplasia. These financial disclosures follow more than three decades of development in neuroscience, with several compounds currently positioned in mid- to late-phase clinical trials.